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Objective
•To evaluate the effect of melatonin on nocturia in Parkinson’s disaese
Methods
•This was an open label clinical trial of sustained-release
Melatonin 2mg once daily for 6 weeks in patients with PD. We
included over 18 year old patients reporting nocturia based on to
NMSQuest item 9 –“Getting up regularly at night to pass urine”
two or more times at night. Clinical examination and urodynamics
were done at the beginning of the study. We excluded patients on
Z drugs or clonazepam, cognitive decline (MOCA score <26), REM
sleep behaviour disorder. Male patients found to have enlarged
prostate, patients with urinary infection, significant retention on
bladder scan, or bladder outflow obstruction on urodynamics
were excluded.
•Assessments included urinary symptoms and quality of life
questionnaires, bladder and sleep diaries Data of awakenings and
quality of sleep was recorded using wrist accelerometer worn
two weeks prior to starting melatonin, and during treatment.
•The primary analysis of “bother related to nocturia” compared
the endpoints before (week 0) and whilst on treatment (week 6).
•Secondary outcomes were1) Mean number of nocturia episodes
per night 2) Nocturnal voided volumes 3) Lower urinary tract
symptoms
4) Sleep disturbances and quality of sleep 5) Quality of life
6) Sleep disturbance in partners/carers 7) Safety
Results
•27 patients were recruited, however, only 18 completed the entire
trial. Patients were eliminated because of lack of interest, logistical
problems, failure to meet exclusion criteria and on one occasion
due to failed urodynamic testing. 10 males and 8 females
completed the study, which is representative as both males and
females are affected by the disease, yet is 1.5 times more prevalent
in males (Moisen et al, 2015). The mean age of participants in this
study was 67.72, with a Standard Deviation (SD) of 7.18. The mean
Hoehn and Yahr (H&Y) score for the severity of Parkinson’s was
2.29, with a standard deviation of 0.47, which is an average PD
severity score. Because of the significant improvement, five
participants asked their GPs to continue taking melatonin after the
trial.
Conclusion
•In this open label phase IIb study, Melatonin was safe and
reduced the mean frequency of voids and improves nocturia
in PD. A significant benefit in sleep outcomes was observed.
A larger multicenter phase III study can help consolidate










ICIQ-N 3.83 3.00 -0.83 0.01346*
Nocturia-Related 
Bother
5.33 3.94 -1.38 0.06931
USP 9.56 8.84 -0.61 0.5688
OAB 7.44 6.67 -0.78 0.1946
SFQ 1.58 1.29 0.26 0.1156
Outcome Measure: Mean Before Mean After P-Value:
Nocturnal 
Polyuria index
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• History & 
Examination
• Questionnaires
• Sleep/Bladder diaries (weeks 1 
and 2)
• Prolonged-release melatonin 2mg 
once-daily for 6 weeks
• Weekly phone call from research 
nurse
• Questionnaires




Table 3. The outcome measures of sleep quality from the sleep diary, PSQI and 
PDSS.
Table 1 The Wilcoxon Ranked Test Sum test statistics for outcome measures of bladder 
symptoms from the ICIQ-N, USP and SF-Qualiveen.
Table 2 The outcome measures of Nocturnal Polyuria index and frequency of 
nighttime voids calculated from the FVC.
Grant reference: K-1303
Background
•Nocturia is one of the commonest non motor symptoms in
Parkinsons’ disease (PD), and has a highly significant negative impact
on quality of life, affecting both the patients and their carers. It has
been demonstrated that nocturia could be due to increased
production of urine at night due to impaired circadian rhythm. We
aimed to improve circadian regulation with melatonin with the aim to
control symptoms and disability related to nocturia.
